4/A: GeneDx Holdings CFO Kevin Feeley Amends Form 4 Filing to Correct Stock Sale Reporting
SEC Form 4/A (Amendment)
Kevin Feeley, CFO of GeneDx Holdings Corp., amended his Form 4 filing to correct a previously reported error in the amount of Class A Common Stock sold following a stock option exercise.
Summary
- Kevin Feeley, the CFO of GeneDx Holdings Corp., filed an amended Form 4 with the SEC.
- The amendment corrects an error in the original filing from April 10, 2025, regarding the amount of Class A Common Stock sold in connection with a stock option exercise.
- On April 9, 2025, Feeley exercised an employee stock option to acquire 1,246 shares at $32.67 per share.
- Feeley then sold shares of Class A Common Stock in multiple transactions at varying prices, ranging from $83.6689 to $97.26 per share.
- The sales were executed under a Rule 10b5-1 trading plan adopted on August 21, 2024.
- After these transactions, Feeley directly owns 2,972 shares of Class A Common Stock and 7,473 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.
Industry Context
This filing is a routine disclosure related to insider trading activity and is common for publicly traded companies. It provides transparency into the transactions of company executives.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
- Companies like Illumina, Inc. and Myriad Genetics, Inc., which are also in the genetic testing and diagnostics industry, have similar insider trading reporting requirements.
- The Rule 10b5-1 trading plan is a common tool used by executives to avoid accusations of insider trading, and its use is widespread among publicly traded companies.
Stakeholder Impact
- The correction of the Form 4 filing ensures accurate information is available to shareholders regarding insider transactions.
- This promotes transparency and trust in the company's governance.
Key Dates
| Date | Description |
|---|---|
| 08/21/2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 12/01/2022 | Commencement date of quarterly vesting installments for the employee stock option |
| 04/09/2025 | Date of stock option exercise and subsequent sales of Class A Common Stock |
| 04/10/2025 | Date of original Form 4 filing (amended) |
| 05/09/2025 | Date of amended Form 4 filing |
| 08/31/2032 | Expiration date of the Employee Stock Option |
Keywords
Form 4, GeneDx Holdings, Kevin Feeley, Stock Sale, Insider Trading, SEC Filing, Amendment, Rule 10b5-1, CFO, WGS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.